Zoetis Securities Fraud Class Actions
Analysis based on 316 articles · First reported May 18, 2026 · Last updated Jul 19, 2026
The class action lawsuits against Zoetis for alleged securities fraud have negatively impacted investor confidence and the company's stock price. The allegations of misleading statements regarding product performance and market share, coupled with reduced profit guidance, have led to significant losses for shareholders. The ongoing legal proceedings and potential financial liabilities could further pressure Zoetis's market valuation.
Multiple law firms, including Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, DJS Law Group, Bragar Eagel & Squire, Rosen Law Firm, and The Law Offices of Frank R. Cruz, have filed class action lawsuits against Zoetis Inc. The lawsuits allege that Zoetis made materially false and misleading statements to investors between January 14, 2025, and May 6, 2026, regarding the growth, competitive positioning, market share, and veterinarian adoption of its Companion Animal segment products. Specifically, the complaints highlight weakening prescription growth for Bedinvetmab due to FDA safety warnings, loss of market share for Sarolaner to lower-priced competitors, and substantial market share loss for dermatology products Oclacitinib and Lokivetmab to new treatments. These issues were allegedly not disclosed, leading to investor losses when Zoetis reported disappointing first-quarter 2026 financial results and cut its full-year profit guidance, causing its stock price to fall by 21.5%. Investors have until July 27, 2026, to seek lead plaintiff status in these lawsuits.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard